Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous IL-12-Engineered AML Cells in AML
NCT02483312Phase 1Active, not recruiting
- Sponsor
- University Health Network
- Start
- Sep 2015
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous interleukin-12-expressing acute myeloid leukemia cells in acute myeloid leukemia (AML), sponsored by University Health Network. Primary endpoint: Number of side effects by type and severity at 2 years. Started Sep 2015; status: active, not recruiting.
02
Drugs
autologous interleukin-12-expressing acute myeloid leukemia cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02483312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483312.